Single‐Dose, Long‐Acting Injectable Buprenorphine for Opioid Withdrawal Treatment

Given the stability of OAT patients on LAIB, it was inferred that some patients may do well in opioid withdrawal management using LAIB, should other conventional treatments not succeed. This was based on previous pharmacokinetic data and modelling by others which would allow for a slow, in vivo wean of the drug rather than discrete, daily dose reductions. For patients, this could reduce potential withdrawal symptoms and shorten admission lengths in hospital withdrawal management wards. Further research is needed to verify these results, but these preliminary data are encouraging.